5Simoens S, Bruyn K D, Bogaert M, et al . Pharmaceutical policy regarding generic drugs in Belgium[J]. Pharmacoeconomics, 2005,23(8): 755-766,
6Walkom E, Robertson J. Newby D, et al . The role of pharmacoeconomics in formularydecision-making [J]. Health Module, 2006,41(8): 374-380.
7Anis A H, Gagnon Y. Using economic evaluations to make formulary coverage decisions-somuch for guidelines [ J ]. Pharmacoeconomics,2000, 18(1): 55-62.
8Claxton K, Sculpher M, Drummond M . A rational framework for decision making by the National Institute for Clinical Excellence(NICE)[J].The Lancet. 2002, 360: 711-715.
9Anell A, Svarvar P . Pharmacoeconornics and clinical practice guidelines[Jl. Pharmacoeconomics, 2000, 17(2): 175-185.
10Velden M E, Severens J L, Novak A . Economic evaluations of heahhcare programmes anddecision making-The influence of economic evaluations on different heahhcare decision-making levels[J].Pharmacoeconomics, 2005, 23( 11 ) : 1 075-1 082.
